Status:
UNKNOWN
Interventional Study on DEterminants and Factors of Physical ACtivity After Treatments in Oncology
Lead Sponsor:
Université Sorbonne Paris Nord
Collaborating Sponsors:
Ligue contre le cancer, France
Garmin International
Conditions:
Breast Cancer
Colo-rectal Cancer
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Benefits of physical activity (PA) as supportive care in cancer have been widely demonstrated by the scientific community. However, survivors who have completed chemo-radio-immunotherapy treatments do...
Detailed Description
In 2008, 3 million French people had experienced cancer in the last 15 years, compared to 18 million in 2022. Post-treatment marks a break with the intensive care pathway. It frequently leads to chang...
Eligibility Criteria
Inclusion
- 18 years ≤ age \< 75 years
- survivors of primary non-metastatic breast, lung, prostate or colorectal cancer (stage I, II or III and primary, second and relapse included)
- 3 weeks to 20 years post-treatment (surgery, chemotherapy, radiation therapy and/or immunotherapy) not including hormonal therapy
- Whose ability to participate in the APA intervention has been certified by a medical certificate issued by physician
- Availability and willingness to invest in the DEFACTO study during the program (3 months) and during the post-program follow-up (12 months)
- Participating, on average, in no more than 150 minutes of moderate physical activity or no more than 75 minutes of vigorous activity per week
- Average at least 6 hours a day of sedentary behaviours
- Able to read, understand and complete questionnaires in French
- Able to use connected device (Vivosmart4®) and to perform simple operating actions (press a button, recharge the battery)
- possessing a smartphone which can download Garmin Connect application ®
- Able to walk unassisted
- French speaking and living in France
- having signed the consent form
Exclusion
- Current evidence of metastatic disease
- Having an absolute contraindication by a physician to practice PA
- Using treatments that influence blood pressure, cardiotoxic drugs, painkillers (morphinics);
- Using cane or walking aid
- Deprived of liberty by judicial or administrative decision
- Person under guardianship or curatorship
- Pregnancy and/or lactating women
- Being diagnosed of any cardiac abnormalities
Key Trial Info
Start Date :
March 29 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05354882
Start Date
March 29 2022
End Date
December 1 2023
Last Update
May 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laboratoire Educations et Promotion de la Santé UR3412
Bobigny, France, 93017